ClinicalTrials.gg
RecruitingNCT07278921MosuOSSHSRUpdated Feb 3, 2026

Study to Evaluate the Response to Treatment With Mosunetuzumab in Relapsed/Refractory Follicular Lymphoma (FL) After at Least Two Lines of Therapy, Within the Compassionate Use Program (CUP).

An observational study in Relapsed/Refractory Follicular Lymphoma, sponsored by Andrés José Maria Ferreri. Recruiting at 1 site in Italy. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-02-03.

Sponsored by Andrés José Maria Ferreri · Observational

How we know

From the registry’s dates

  • Started Dec 2025; still recruiting 11 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Other
Time perspective
Retrospective
Enrollment
25
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 149 studies in Lymphoma, Follicular with a site in Italy — 31 open to participants now, 57 under way, 19 of them phase 3. Lymphoma, Follicular · Italy.

Planned enrollment
17th of 17
25 · median 200
Started
2025
with 6 others
Observational
17 of 149
6 open now
Primary completion
2026-12
later than 15 of 56 live
Registered
145th of 149
by date

Among the 149 studies in Lymphoma, Follicular with a site in Italy, this one is the 17th largest by planned enrollment of the 17 observational ones that give a count, is one of 7 that started in 2025, is one of 17 observational ones, reaches primary completion later than 15 of the 56 other live ones, and was the 145th registered.

Lymphoma, Follicular

1,893 studies on the registry are indexed under Lymphoma, Follicular; 289 are open to participants now.

Browse Lymphoma, Follicular studies →

Open to participants now

31 of the 149 studies in Lymphoma, Follicular with a site in Italy are open now. Recruiting first, the newest first:

25 more — sign in →

All 31 open studies →

A study can be open while its sites in Italy have not opened yet or have stopped. Only those recruiting at a site in Italy →

Who these studies take

Of the 226 Lymphoma, Follicular studies recruiting now, 158 (70%) set no upper age limit and 39 (17%) stop at 75 or younger; 34 take children under 18; 23 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 149 studies in Lymphoma, Follicular with a site in Italy, or all of them as a file.
02

Study summary

Retrospective, multicenter observational study to evaluate the response to treatment with Mosunetuzumab in relapsed/refractory Follicular Lymphoma (FL) after at least three lines of therapy, within the Compassionate Use Program (CUP).

03

Conditions studied

  • Relapsed/Refractory Follicular Lymphoma
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Descriptive study of the Italian experience with the compassionate use of mosunetuzumab.

Sample size: approximately 25 patients

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adult patients (>18 years) with follicular non-Hodgkin's lymphoma, undergoing at least two , treated with mosunetuzumab under a compassionate use program.
  • Patients who have signed for treatment.

Exclusion criteria

Exclusion Criteria:

  • Age \<18 years
  • Patients with other types of cancer/lymphoma
  • Patients not eligible for the Mosunetuzumab compassionate use program
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Other
Time perspective
Retrospective
Enrollment
25 participants (estimated)
Patient registry
No

Interventions

  • Adult patients (\>18 years) with Follicular Non-Hodgkin Lymphoma, who have undergone at least two lines of therapy, treated with Mosunetuzumab under a compassionate use program

06

What researchers measure

Primary outcomes

  1. Evaluate the response to Mosu (Lugano criteria)

    The primary objective of the study is to evaluate the response to mosunetuzumab in patients diagnosed with follicular lymphoma from second-line therapy, within the national compassionate use program (CUP). This response is assessed according to the 2014 Lugano criteria.

    Time frame: Up to 1 year from treatment initiation

  2. Disease-free survival (PFS)

    Disease-free survival (PFS) at 1 year is evaluated.

    Time frame: 1 year after starting treatment (PFS at 1 year)

Secondary outcomes

  1. OS

    The study's secondary objective is to evaluate the overall survival (OS) of the included patients.

    Time frame: 12 month

  2. rate of toxicity

    Analyze the rate of toxicity recorded during therapy, with particular attention to infusion reactions, CRS, and ICANS.

    Time frame: 12 months

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Dec 2025 (actual). Primary completion is estimated for Dec 2026, 12 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 21, 2025
First posted
Dec 12, 2025
StartActual
Dec 1, 2025
Primary completionEst.
Dec 31, 2026
CompletionEst.
Dec 31, 2026
Last update
Feb 3, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 3, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07278921
Lead sponsor
Andrés José Maria Ferreri
Responsible party
Andrés José Maria Ferreri (Prof., IRCCS San Raffaele) — Sponsor-investigator
First posted
Dec 12, 2025
Start date
Dec 1, 2025
Primary completion
Dec 31, 2026 (estimated)
Completion
Dec 31, 2026 (estimated)
Last update
Feb 3, 2026

Study contacts

Andres JM Ferreri, Prof
Contact
ferreri.clinicaltrials@hsr.it
0226439396

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion